Lumen Gentium (The Light of Nations), the Vatican II constitution on the Church, marks its 60th anniversary Nov. 21. As a “dogmatic constitution” of an ecumenical council, it is officially one of the ...

The universal call to holiness is a signature teaching of the Second Vatican Council. The topic forms the subject of the fifth chapter of Lumen Gentium, the Council’s dogmatic constitution on the ...

As Jazz Pharmaceuticals ($JAZZ) rolls on with an orphan drug deal spree, shareholders of Gentium ($GENT), its latest target, are suing to stop the acquisition, saying ...

The CHMP had issued the negative opinion in Mar 2013. Gentium is looking to get the candidate approved for treating and preventing hepatic veno-occlusive disease (VOD) in adults and children ...

VILLA GUARDIA (COMO), Italy, Nov 09, 2009 (BUSINESS WIRE) -- Gentium S.p.A. (Nasdaq: GENT) announced today the members of its new Board of Directors and the appointment of an Interim CEO. The new ...

Pope Paul VI presides over a 1963 session of Vatican II. Credit: CNS photo/Catholic Press Photo. The constitution, wrote America associate editor Donald R. Campion, S.J., shortly after its publication ...

Italy's Gentium has suffered a major setback after it emerged that the European Medicines Agency is likely to turn down defibrotide, its investigational treatment for hepatic veno-occlusive disease.

Jazz Pharmaceuticals ( JAZZ) has entered into a definitive agreement to acquire biopharma company Gentium ( GENT) for $57.00 per share in cash or $1 billion. The offer price of $57.00 per share ...

Italian drugmaker Gentium has pulled its US marketing application for defibrotide, a drug for veno-occlusive disease (VOD), after it became clear that the Food and Drug Administration would not accept ...

Jazz Pharmaceuticals Plc, the maker of the narcolepsy treatment Xyrem, agreed to buy Gentium SpA, a rare-disease drug developer, in a deal valued at $1 billion. Jazz, based in Dublin, will pay $57 a ...

(Reuters) - Ireland-based Jazz Pharmaceuticals Plc said it would buy Italian biotech company Gentium S.p.A. for about $1 billion to get access to its lead product candidate, Defitelio, a drug used for ...